Stay updated with breaking news from Jiangbing Zhou. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Couragene, a genetic medicines company using novel delivery platforms, announces today that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University, together with Elizabeth Berry-Kravis of RUSH University have been awarded a competitive UG3/UH3 grant from the NIH’...
The two-phase grant will support research into a novel CRISPR-based gene-editing technology and delivery platform for targeting neurogenetic diseases.
The National Institute of Health announced a $40 million grant for researchers to develop a CRISPR-mediated platform for genome editing in the brain and to treat genetic disorders.
Stroke-Targeting Nanoparticles Deliver Neuroprotectant to Mouse Brain Written by AZoNanoMar 12 2021 According to a new study, the delivery of NA1, a neuroprotectant, to the brain in nanoparticles decreases stroke severity and enhances survival in a mouse model of stroke. Image Credit: Alexandros A Lavdas/shutterstock.com This is a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2021. The virtual meeting will be held from March 17 th to 19 th, 2021, and is a world premiere meeting for clinicians and researchers committed to the science ...
E-Mail DALLAS, March 11, 2021 -- When NA1, a neuroprotectant, was delivered to the brain in nanoparticles, it reduced stroke severity and improved survival in a mouse model of stroke, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021. The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health. In an earlier human trial (the ESCAPE-NA1 trial), NA1, a small peptide designed to save brain cells from death after stroke, showed ...